Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma

Background Deregulated Notch signaling is implicated in multiple cancers. The phase I trial (I6F-MC-JJCA) investigated the safety and anti-tumor activity of crenigacestat (LY3039478), a selective oral Notch inhibitor, in an expansion cohort of patients with adenoid cystic carcinoma (ACC) who receive...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Even, C., Lassen, U., Merchan, J., Le Tourneau, C., Soria, J-C, Ferte, C., Ricci, F., Diener, J. T., Yuen, E., Smith, C., Oakley, G. J., Benhadji, K. A., Massard, Christophe
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2019
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066312/
https://ncbi.nlm.nih.gov/pubmed/30953269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00739-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados